Viewing nowPrincapsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

MFDS item code 201604075 · Approved 2016.06.29 · Insurance code 663607020
Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures in epilepsy, and treatment of fibromyalgia
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive treatment for partial seizures in patients with epilepsy, regardless of the presence of secondary general symptoms. Additionally, it helps relieve symptoms of fibromyalgia. It is effectively used for various neurological disorders and pain management.
Administer the total daily dose of pregabalin orally in 2 divided doses, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section '5. Patients with renal impairment') 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section '4. Discontinuation') 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily) and, based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering dose-dependent adverse reactions, administration of doses exceeding 450 mg daily is not recommended. 4. Discontinuation Based on current clinical experience, if this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys unchanged. Since its clearance is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained using the above formula by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration method Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Divide the total daily dose into 3 doses BID = Divide the total daily dose into 2 doses QD = Administer once daily a: The total daily dose (mg/day) should be divided as specified under the administration method. b: The supplemental dose is a dose administered once in addition to the regular dose. 6. Patients with hepatic impairment No dose adjustment is required in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication is used as an anticonvulsant, and there may be an increased risk of suicidal thoughts or behaviors; thus, mood and behavior changes should be closely monitored during treatment. Patients with hypersensitivity to this drug or specific genetic issues such as lactose intolerance should not take this medication. Diabetic patients may need to adjust their blood sugar medication dosage due to weight gain, and should stop taking this medication immediately if signs of angioedema occur. Elderly patients should exercise caution due to risks of dizziness or drowsiness leading to falls, and may experience vision changes such as blurred vision. Withdrawal symptoms such as insomnia, headache, and anxiety may occur if the medication is abruptly discontinued, so consultation with healthcare professionals is advised. Patients with a history of drug abuse should be cautious of the potential for misuse of this medication. Patients with heart disease or renal dysfunction should consult with healthcare professionals before administration, and dose adjustments may be necessary in cases of severe respiratory depression in those with respiratory disorders or the elderly. Pregnant women should not take this medication during the early stages of pregnancy as it may pose risks to the fetus, and women of childbearing age should use effective contraception. Caution should be taken while driving or operating machinery due to risks of dizziness and drowsiness. This drug can cause serious skin reactions such as rash and Stevens-Johnson syndrome, so if any unusual symptoms occur, it should be discontinued immediately, and healthcare professionals should be notified. When used with other central nervous system depressants or opioid analgesics, the risk of respiratory depression increases, necessitating careful monitoring. In case of overdose, symptoms may include drowsiness, confusion, and depression, and treatments like hemodialysis may be necessary. Dosage adjustments are needed for children and the elderly, and consulting healthcare professionals is mandatory before administration to children, pregnant women, or nursing mothers. Keep the medication out of reach of children and do not transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture, preferably at room temperature between 15 to 30 degrees Celsius.
A hard capsule with an upper reddish-brown part and a lower white part containing a powder that is white to pale yellow.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.